TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06449508
Drug: Probiotic Formula
Normalized name: Probiotic Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: drops of probiotic supplement containing bacillus clausil spores (Enterogermania Amp 2 Billion/5Ml )
Study: NCT05551689
Drug: Psychostimulant
Normalized name: Psychostimulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: All enrolled patients should be receiving ADHD pharmacological treatment (psychostimulants)
Study: NCT05823246
Drug: QLF31907
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion once every two weeks. The dose administered in part 2 will depend on the outcome of part 1.
Study: NCT05742568
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
Study: NCT06286475
Drug: VRG50635
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06286475
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT04684589
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in this arm will be provided with 20mg Placebo to take every day for 12 weeks, beginning at their baseline visit.
Study: NCT05117749
Drug: Saffron 100
Normalized name: SAFFRON
Approvals — FDA: no, EMA: no, PMDA: no
Description: to Mild and Moderate UC patients
Study: NCT05117749
Drug: Saffron 50
Normalized name: SAFFRON
Approvals — FDA: no, EMA: no, PMDA: no
Description: to Mild and Moderate UC patients
Study: NCT05117749
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: to Mild and Moderate UC patients
Study: NCT06188104
Drug: Trichloroacetic acid
Normalized name: Trichloroacetic Acid
DrugBank: Dichloroacetic acid (DB08809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Applying Trichloroacetic acid 95 % topical solution plus acetic acid at the transformation zone or lesion (if have) of the cervix during colposcopic examination (95% topical trichloroacetic acid is used just before finishing examination, while acetic acid is used normally when perform colposcopy)
Study: NCT05920135
Drug: BBT-207
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BBT-207 given orally alone
Study: NCT06624384
Drug: Group 1 drug
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: In this group, the aim is to compare 2 drugs, cyclosporine 0.05% and Lifitgrast . In one eye, cyclosporine 0.05% eye drops are randomly poured and in the opposite eye, Lifitgrast eye drops are poured.
Study: NCT06624384
Drug: Group 2: Drug and placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: In this group, the aim is to compare 2 drugs, cyclosporine 0.05% and Artelac artificial tear as a placebo. In one eye, cyclosporine 0.05% eye drops are randomly poured, and in the opposite eye, Artelac artificial tear are poured.
Study: NCT06624384
Drug: Group 3: Drug and palcebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3: In this group, the aim is to compare 2 drugs, Lifitgrast and Artelac artificial tear as a placebo. In one eye, Lifitgrast eye drops are randomly poured, and in the opposite eye, Artelac artificial tear are poured.
Study: NCT05861102
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo orally twice daily for 16 weeks
Study: NCT04618211
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules for oral use
Study: NCT06731348
Drug: restricted opioid prescribing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the restricted opioid prescribing group will receive restricted opioid prescribing after surgery. They will receive 1 tablet of Oxycodone HCl 5mg.
Study: NCT06731348
Drug: standard opioid prescribing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive standard opioid prescribing - Oxycodone HCl 5mg x10 tablets for major cases, 5 tablets for minor cases.
Study: NCT06625814
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: single oral dose
Study: NCT06624709
Drug: Iron Supplement
Normalized name: Iron supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: The interventional group will receive 2-3mg/kg/day of iron supplementation 4 times per week and the sham comparator will receive 2-3mg/kg/day of iron supplementation 7 times per week
Study: NCT06730620
Drug: Test preparation：Methylcholine chloroacetate for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinergic agonists
Study: NCT05550441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Placebo group received placebo for 1 year.
Study: NCT05123755
Drug: AV-001 Placebo Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-PBS
Study: NCT05040022
Drug: Pneumoperitoneum pressure 10 mmHg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The abdomen will be inflated with carbon dioxide to maintain the intra-abdominal pressure at 10 mmHg (group 10)
Study: NCT05040022
Drug: Pneumoperitoneum pressure 14 mmHg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The abdomen will be inflated with carbon dioxide to maintain the intra-abdominal pressure at 14 mmHg (group 14).
Study: NCT00001047
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05470816
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline
Study: NCT05236972
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m² po twice daily on days 1- 14 repeated every 21 days
Study: NCT05893069
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo for 12 weeks
Study: NCT06622291
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exogenous nitric oxide is directly administered to the oxygenator in the cardiopulmonary bypass circuit at a concentration of 60 ppm. Nitric oxide is also directly administered to the ventilator at a concentration of 60 ppm for 12 hours post-operation.
Study: NCT05156645
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluted by 0.9% normal saline
Study: NCT05177835
Drug: ABX464
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive ABX464 given at 25 mg QD.
Study: NCT05771402
Drug: NAs
Normalized name: DNase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once/day, 1 capsule/time, oral
Study: NCT06303128
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given prior to amoxicillin 250mg in one-dose group
Study: NCT06420375
Drug: BRS201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groups 1, 2, 3, and 4 will all contain 5 subjects each, with each subject receiving active study drug and placebo in a 3:2 randomized order; 3 will receive active treatment for the first for four weeks followed by placebo for four weeks, while the remaining 2 will receive placebo for four weeks followed by active treatment for four weeks.
Study: NCT06420375
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groups 1, 2, 3, and 4 will all contain 5 subjects each, with each subject receiving active study drug and placebo in a 3:2 randomized order; 3 will receive active treatment for the first for four weeks followed by placebo for four weeks, while the remaining 2 will receive placebo for four weeks followed by active treatment for four weeks.
Study: NCT05801900
Drug: Ibuprofen group
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 30 min preoperatively then every 8 hours postoperatively
Study: NCT05595408
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: cisplatin/carboplatin-gemcitabine 4-6 cycles
Study: NCT06120673
Drug: Oral prednisolone and cyclophosphamide
Normalized name: prednisolone and antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a combination of oral prednisolone and cyclophosphamide with 2 options (Option A and B).~Option A: Cyclical prednisolone and cyclophosphamide with IV methylprednisolone~* IV methylprednisolone 500-1000 mg will be given on days 1, 2 and 3 at the start of months 1, 3, and 5.~* Oral prednisolone will be given at 0.5 mg/kg/day (max 50 mg/day) in months 1, 3, and 5.~* Oral cyclophosphamide will be given in months 2, 4 and 6, adjusted by age and weight~Option B: Concurrent prednisolone and cyclophosphamide without IV methylprednisolone~* Oral prednisolone will be given to meet a cumulative dose equivalent to 0.5 mg/kg/day for 90 days (max 50 mg/day).~* Oral cyclophosphamide will be given for 90 days, adjusted by age and weight
Study: NCT05320068
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A blinded capsule that contains no vancomycin every 6 hours during 10 days.
Study: NCT04865211
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of saline as placebo for local anesthesia
Study: NCT05693545
Drug: intramuscular benzathine penicillin G (BPG) prophylaxis
Normalized name: Penicillin G Benzathine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis
Study: NCT06304740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Injection of Placebo
Study: NCT05020704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT04994561
Drug: Study Drugs and Nutritional Supplements
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step 1: 500 mg of metformin and increase their dose 500 mg every 2 weeks up to 2000 mg or until tolerable.~Step 2: Once at tolerable daily metformin dose, subjects will take 140 mg of dasatinib along with 58 mg to 174 mg (based on body weight) bio-quercetin and 44.5 mg bio-fisetin. Subjects will take dasatinib, bio-quercetin and bio-fisetin for 2 consecutive days as described 4 times over one year (every 3 months) while participating on this study.~Step 3: Two weeks after the first dasatinib dose is complete, subjects will start taking daily nutritional supplements of 1,500 mg glucosamine, 600 mg nicotinamide riboside and 500 mg trans-resveratrol.~Step 4: Two weeks after starting daily supplements in Step 3, subjects will take a once weekly 6 mg dose of rapamycin.~Once subject is taking rapamycin, they will continue on this intervention for 12 months.
Study: NCT05071716
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Twice Daily
Study: NCT06163053
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors in approved indications
Study: NCT06189404
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg oral dose
Study: NCT05727878
Drug: KPI-012
Approvals — FDA: no, EMA: no, PMDA: no
Description: KPI-012 is a secretome product composed of biologically active components secreted from human bone marrow-derived mesenchymal stem cells
Study: NCT05727878
Drug: KPI-012 Vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: KPI-012 formulation with no active drug
Study: NCT00076960
Drug: Stanate (TM) [stannsoporfin, tin-mesoporphyrin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with 4.5 mg/kg
Study: NCT04616014
Drug: ORMD-0801 QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg, QD, two capsules, 8 mg each.
Study: NCT06619665
Drug: MK-6552
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-6552 gelatin coated capsules taken orally two times 8 hours apart
Study: NCT06619665
Drug: MK-6552 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-6552 placebo gelatin coated capsules taken orally two times 8 hours apart
Study: NCT05745207
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2086 matched placebo tablets.
Study: NCT05869682
Drug: Combination Drug Therapy
Normalized name: BILE THERAPY DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive SOC ADT combination therapy
Study: NCT06455124
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine: 1000mg/m2 d1-14 q3w
Study: NCT05497336
Drug: IBI351
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI351 is administered orally
Study: NCT05501327
Drug: SLI-F06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin injection of SLI-F06 at each wound edge after closure of punch biopsy excision.
Study: NCT00365001
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-25mg po/week
Study: NCT00365001
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg po on days 1, 15 and 43
Study: NCT04659629
Drug: NL-201
Approvals — FDA: no, EMA: no, PMDA: no
Description: NL-201 is a de novo protein therapeutic.
Study: NCT06360120
Drug: Rosuvastatin 20mg
Normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The rosuvastatin group consisted of 300 patients who received 40 mg daily rosuvastatin for 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
Study: NCT05804734
Drug: Vitamin K Antagonist - Drug
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only clinical data (number and types of severe bleeding events, HAS-BLED score, CHA2DS2-VASc score) are collected during the follow-up:~* For cases when they received an anticoagulant treatment and during the 12 months preceding this treatment,~* For controls during the same periods of their cross-matched cases when reciving anticoagulant treatment.
Study: NCT06053983
Drug: rosuvastatin 20 mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: The statin are most commonly used agents for prevention of cardiovascular events and recurrent episodes of ACS. Apart from their anti-lipid actions, statins show pleotropic effects which include their anti-inflammatory role. Atorvastatin and rosuvastatin are both members of statin family and have showed their effectiveness in reduction of inflammatory biomarkers in addition to their lipid lowering effects
Study: NCT04485130
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This study will provide disulfiram. Participants in Cohort 1 receiving disulfiram will take 2 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days.
Study: NCT04485130
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study will provide placebo. Participants in Cohort 1 receiving placebo will take 2 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days
Study: NCT05362695
Drug: IW-3300
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose of IW-3300 administered rectally (as a low-volume \[20 mL\] enema).
Study: NCT05362695
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose of placebo administered rectally (as a low-volume \[20 mL\] enema).
Study: NCT06435767
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the Cancer Hospital, postoperative chemotherapy regimens and doses were planned by oncologists, with adjustments made based on drug toxicities or tumor responses.
Study: NCT01134497
Drug: ZD4054
Approvals — FDA: no, EMA: no, PMDA: no
Description: The experimental arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus ZD4054 (10mg daily) od by mouth on days 1-21 of a 21 day cycle.
Study: NCT06098144
Drug: Nicoderm C-Q Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a 6-week supply of nicotine replacement treatment (NRT). Based on participants' self-report on the number of cigarettes smoked, these are the possible dosages of NRT gum (2 mg and 4 mg). Participants should not smoke and use the nicotine gum at the same time. Nicotine gum should only be used when cravings for cigarettes arise and should not be treated like regular chewing gum. It is not to be constantly chewed~NRT will be distributed based on the treatment condition.
Study: NCT05958069
Drug: minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with minocycline combined with antiepileptic drugs: After enrollment, 100mg/day (50mg specification) of minocycline hydrochloride was administered for 12 consecutive weeks;
Study: NCT05094947
Drug: alpha-blockers
Normalized name: ALPHA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: tamsulosin, alfuzosin, doxazosin, silodosin
Study: NCT05978505
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 nightly doses to commence after surgery.
Study: NCT06517173
Drug: Y-3 for injection
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualified subjects were randomly divided into groups in a 1:1 ratio and received continuous treatment with Y-3 injection (40 mg/dose, qd) or placebo control drug. The treatment was performed 10 times for 10 days.
Study: NCT06517173
Drug: Placebo control group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualified subjects were randomly divided into groups in a 1:1 ratio and received continuous treatment with Y-3 injection (40 mg/dose, qd) or placebo control drug. The treatment was performed 10 times for 10 days.
Study: NCT04922359
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received 0.075ml/kg of intravenous normal saline during induction of anesthesia and 0.075ml/kg/h for anesthesia maintenance.
Study: NCT06326684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The effects of placebo will be determined.
Study: NCT05584306
Drug: 610 30mg group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 610 30mg subcutaneous (SC) Q4W，8 times
Study: NCT05584306
Drug: 610 100mg group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 610 100mg subcutaneous (SC) Q4W，8 times
Study: NCT05584306
Drug: 610 300mg group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 610 300mg subcutaneous (SC) Q4W，8 times
Study: NCT05914389
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy from Day 1 to Day 14 every 3 weeks and repeat for 4 cycles. The dose reduction protocol for capecitabine-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.
Study: NCT05914389
Drug: Clostridium butyricum
Normalized name: Clostridium butyricum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clostridium butyricum is treated with Miyarisan 588 powder, 160mg/day (4 packets/day) taken orally for a total of 6 weeks.There have been no reports of adverse reactions for Lactobacillus. There is no predetermined reduction plan.
Study: NCT05288725
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The corticosteroid is prepared in a 10 ml syringe by combining 1-2 mL Kenalog \[40 mg/dL\], 6-8 mL sterile normal saline, 3-4 mL Ropivicaine 1%.
Study: NCT06730282
Drug: Danggui Shaoyao San (DSS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danggui Shaoyao San is a traditional Chinese medicine (TCM) formula used to regulate blood flow, alleviate pain, and reduce inflammation. Participants in this arm will receive DSS starting 3 to 7 days before menstruation and continue until 3 days after menstruation for two cycles.
Study: NCT06730282
Drug: Cuscuta Chinensis (Tu Si Zi)
Normalized name: Cuscuta chinensis seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cuscuta Chinensis is a TCM formula traditionally used to nourish kidney essence and improve menstrual health. Participants in this arm will receive Tu Si Zi starting 3 to 7 days before menstruation and continue until 3 days after menstruation for two cycles.
Study: NCT05850286
Drug: VRD-based Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib, Lenalidomide and Dexamethasone
Study: NCT06730282
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this arm will receive a placebo that matches the appearance of the study medications. The placebo will be administered on the same schedule as the active treatments for two menstrual cycles.
Study: NCT05841238
Drug: LY3502970
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05433480
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 400 mg, orally once daily
Study: NCT06055023
Drug: ZL-82 12.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 case,The starting dose,Take the medicine once on D1,D1-7.
Study: NCT06055023
Drug: ZL-82 25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 case,The starting dose,Take the medicine once on D1,D1-7.
Study: NCT06055023
Drug: ZL-82 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 case,The starting dose,Take the medicine once on D1,D1-7.
Study: NCT06055023
Drug: ZL-82 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 case,The starting dose,Take the medicine once on D1,D1-7.
Study: NCT06055023
Drug: ZL-82 200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 case,The starting dose,Take the medicine once on D1,D1-7.
Study: NCT06055023
Drug: ZL-82 300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 case,The starting dose,Take the medicine once on D1,D1-7.
Study: NCT06055023
Drug: ZL-82 450mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 case,The starting dose,Take the medicine once on D1,D1-7.
Study: NCT06055023
Drug: ZL-82 600mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 case,The starting dose,Take the medicine once on D1,D1-7.
Study: NCT05037539
Drug: Fentanyl Citrate 50Mcg/Ml Inj_#1
Normalized name: FENTANYL CITRATE 50MCG/ML INJ_#1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable Fentanyl in Sublingual Route 50 mcg